H.C. Wainwright maintained a positive stance on Esperion Therapeutics (NASDAQ:ESPR) shares, reaffirming a Buy rating and a price target of $16.00. According to InvestingPro data, analyst targets for ...

JMP Securities adjusted its price target for Esperion Therapeutics (NASDAQ:ESPR) shares, lowering it to $4.00 from the previous $7.00. Currently trading at $1.86, the stock sits well below analyst ...

JMP Securities lowered the firm’s price target on Esperion (ESPR) to $4 from $7 and keeps an Outperform rating on the shares. JMP updated its ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Enanta Pharmaceuticals ...

Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) ...

Bempedoic acid is under clinical development by Esperion Therapeutics and currently in Phase II for Hypercholesterolemia. According to GlobalData, Phase II drugs for Hypercholesterolemia have a 57% ...

Investing.com -- Shares of Esperion (NASDAQ:ESPR) Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December 31, ...

Investing.com -- Shares of Esperion (NASDAQ:ESPR) Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December ...

Esperion Therapeutics (ESPR), another stock in the same industry, closed the last trading session 2.6% lower at $2.28. ESPR has returned 4% in the past month. Esperion Therapeutics' consensus EPS ...